about
Paroxetine versus other anti-depressive agents for depressionFluoxetine versus other types of pharmacotherapy for depressionDrug dose as mediator of treatment effect in antidepressant drug trials: the case of fluoxetine.New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base.Antipsychotic drug exposure and risk of myocardial infarction.Antipsychotic combinations in schizophrenia.Benzodiazepines and risk of dementia: true association or reverse causation?Focused psychosocial interventions for children in low-resource humanitarian settings: a systematic review and individual participant data meta-analysis.Can a digital medicine system improve adherence to antipsychotic treatment?Psychological therapies for the treatment of mental disorders in low- and middle-income countries affected by humanitarian crisesEfficacy and acceptability of antidepressants in patients with ischemic heart disease: systematic review and meta-analysisMediators of focused psychosocial support interventions for children in low-resource humanitarian settings: analysis from an Individual Participant Dataset with 3,143 participantsAntipsychotic use and risk of life-threatening medical events: umbrella review of observational studiesEsketamine for treatment resistant depression: a trick of smoke and mirrors?Are trials of psychological and psychosocial interventions for schizophrenia and psychosis included in the NICE guidelines pragmatic? A systematic reviewEsketamine clinical trials: reply to Maju et alPoor implementation of the EU clinical trial regulation is a major threat for pragmatic trials in European countries
P50
Q24197507-31A3BCB2-7343-4DAB-B36D-B2CEC29B93F5Q24201165-8EA27D90-1088-4439-9DDC-76FC342AAE47Q38286223-9ED477A0-2173-4305-9411-09BECA1A995EQ38779397-54D97163-7E06-4921-A017-9C88D91AF11CQ39016420-CC5AD9C0-49EC-4C0E-BD74-4530EF62F56CQ39348889-DBE7A299-E4AB-403E-BD3B-8186EDB791C6Q45158347-0CEDD4AD-12A4-4EA8-8707-83ADF97869C7Q51763869-DD795548-5817-4F04-BE6B-643DB3DD90EBQ52661294-1509A647-B193-473F-A6BA-2CD298A07F5CQ56888598-8400D993-35FE-42C4-8029-7B148E17D053Q90369449-FA611C41-362B-47E2-86E1-1E428C5CE53BQ91181330-82AF8111-BF65-4E93-8073-D284BF35DC01Q91543881-4386372C-69E7-4F0F-969F-CD833CA7A308Q92003437-9E6D3601-E4FE-447F-9459-E8ACE8DAACDCQ94069533-A0CAA775-3982-4EBF-BBCC-40C66F1F6347Q94451007-0AF4E963-59B1-4EF4-8551-96125BDD9827Q94547697-E846E4B2-6066-4C3F-B0AA-6C147587722B
P50
description
investigador
@es
researcher
@en
name
C Gastaldon
@en
type
label
C Gastaldon
@en
prefLabel
C Gastaldon
@en
P31
P496
0000-0001-7257-2962